Pain
News from the FDA/CDC
FDA approves Reyvow for acute migraine treatment
The approval of lasmiditan (Reyvow) is based on a pair of randomized, double-blind, placebo-controlled trials that included more than 3,000...
Feature
Novel research aims to improve ED care in sickle cell disease
Researchers are testing the best acute pain management strategies to respond to a vasoocclusive crisis.
News from the FDA/CDC
CDC finds that too little naloxone is dispensed
Despite increases in the number of naloxone prescriptions dispensed, many patients at risk for overdose are not offered the potentially life-...
Conference Coverage
Posttraumatic headache may be associated with reduced pain thresholds
PHILADELPHIA – Symptoms of photophobia and allodynia are more severe in patients with posttraumatic headache,...
Conference Coverage
Medication overuse prevalent among U.S. migraine patients
PHILADELPHIA – Results from a U.S. survey showed an 18% prevalence of medication overuse among people with self-reported migraine symptoms.
From the Journals
Almost one-third of ED patients with gout are prescribed opioids
A diagnosis of diabetes or polyarticular gout attack, and prior opioid use were all associated with a more than 100% higher odds of opioid...
Latest News
Medical cannabis laws appear no longer tied to drop in opioid overdose mortality
"Cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,"...
From the Journals
Gabapentinoids associated with suicidal behavior, overdose
Pregabalin is associated with greater risk, compared with gabapentin, and the associations are strongest in patients aged 15-24 years.
Feature
Opioid prescriptions declined 33% over 5 years
The number of opioid prescriptions decreased 33% nationally from 2013 to 2018, according to the new report from the American Medical Association...
From the Journals
When adolescents visit the ED, 10% leave with an opioid
Compared with outpatient clinics, prescription rate is more than six times higher in the emergency department.
Conference Coverage
Tanezumab acts fast for OA pain relief
TORONTO – The nerve growth factor inhibitor separated from placebo in the first 3-5 days in a phase 3 randomized, controlled trial.